Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690155 | 0.92 | DRD2 (0.47) | DRD2CACNA1HMEN1ALDH1A1TSHR | |
| SCHEMBL22703621 | 0.92 | DRD2 (0.54) | DRD2CACNA1HMEN1ALDH1A1TSHR | |
| SCHEMBL31452925 | 0.88 | MEN1 (0.66) | DRD2CACNA1HMEN1ALDH1A1TSHR | |
| SCHEMBL24811481 | 0.87 | CACNA1H (0.52) | DRD2CACNA1HMEN1ALDH1A1TSHR | |
| SCHEMBL14708214 | 0.84 | CACNA1H (0.52) | DRD2CACNA1HMEN1ALDH1A1TSHR | |
| SCHEMBL24951961 | 0.84 | DRD2 (0.53) | DRD2CACNA1HJAK2JAK1EPHX1 | |
| SCHEMBL16480069 | 0.84 | CACNA1H (0.54) | DRD2CACNA1HJAK2JAK1EPHX1 | |
| SCHEMBL9281583 | 0.84 | SMN1; SMN2 (0.50) | MEN1ALDH1A1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL31301242 | 0.83 | DRD2 (0.63) | DRD2CACNA1HMEN1ALDH1A1KMT2A | |
| SCHEMBL14614740 | 0.83 | CACNA1H (0.53) | DRD2CACNA1HJAK2JAK1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-19 | — | — | US | disclosed |
| EP-3941900-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | Deutsches Krebsforschungszentrum (DE) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020193431-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020193431-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | HDAC10, HDAC1, HDAC11 | DRD2 4710/4885CACNA1H 3750/4885MEN1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.